期刊文献+

HPLC法测定富马酸卢帕他定片剂的含量及有关物质 被引量:1

Determination of Rupatadine Fumarate and the Related Substances in Rupatadine Fumarate Tablets by HPLC
暂未订购
导出
摘要 目的:建立高效液相色谱法测定富马酸卢帕他定片剂含量及有关物质的方法。方法:色谱柱:Dimonsil C_(18)(200 mm×4.6 mm,5μm);流动相:甲醇-2.5 mmol·L^(-1)庚烷磺酸钠溶液(75:25);柱温:30℃;检测波长:247 nm;流速:1.0 ml·min^(-1)。结果:富马酸卢帕他定的线性范围为0.026 6~0.424 8 mg·ml^(-1)(r=0.999 9),平均回收率为100.2%(RSD=0.9%,n=9),片剂中有关物质的含量<1%。结论:建立的方法操作简单、结果准确、专属性强、重复性好,可用于富马酸卢帕他定片剂中有关物质检查及主药含量测定。 Objective: To establish an HPLC method for the quantitative analysis of rupatadine fumaxate and the related substances in rupatadine fumarate tablets. Method: The determination was performed on Dimonsil Cis chromatographic column (200 mm× 4.6 mm,5 μm) at 30 ℃. The mobile phase consisted of methanol - 2. 5 mmol·L-1 sodium heptanesulfonate solution (75:25 ) with the flow rate of 1.0 ml·min ^-1 and the detection wavelength at 247 nm. Result: The method showed a good linear relationship within the range of 0. 026 6-0. 424 g mg·ml^ -1 ( r = 0. 999 9, n = 5 ). The average recovery was 100. 2% with RSD of 0. 9% ( n = 9 ). The total content of the related substances in samples was below 1. 0%. Conclusion: The developed method is simple, accurate and reliable, and it can be applied in the determination of rupatadlne fmnarate and the related substances in rupatadine fumarate tablets.
机构地区 武汉大学药学院
出处 《中国药师》 CAS 2011年第5期664-666,共3页 China Pharmacist
关键词 富马酸卢帕他定 高效液相色谱 有关物质 含量测定 Rupatadine fumarate HPLC Related substances Content determination
  • 相关文献

参考文献5

二级参考文献20

  • 1王震宇,朱雄,王尔华.卢帕他定中间体5-甲基吡啶-3-羧酸的合成工艺改进[J].药学进展,2005,29(1):31-33. 被引量:3
  • 2张万金,罗艳,张燕梅.卢帕他定的合成[J].中国医药工业杂志,2006,37(7):433-435. 被引量:7
  • 3Inaki L,Manuel M,Julian G,et al . New selective histamine HI receptor and platelet-activating factor (PAF)antagonlst [J]. Drugs of Today, 2003,39(6) :451-468.
  • 4Merlos M,Giral M,Balsa D,et al . Rupatadine,a new potent,orally active dual antagonist of histamine and platelet-activating factor (PAF) [J]. J Pharmacol Exp Ther, 1997,280: 114-121.
  • 5国家药典委员会.中华人民共和国药典2005年版二部附录VD[M].北京:化学工业出版社.
  • 6ZhongDF.Some aspects in establishing standard curves in bioanalyses with the weighted leastsquires method .药物分析杂志,1996,16:343-346.
  • 7STUEBNER P, HORAK F, ZIEGLMAYER R, et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber [J]. Ann Allergy Asthma lmmuuol, 2006, 96( 1 ) :3744.
  • 8BARBANOIM J, GARCIT-GEA C, ANTONIJOAN R, et al. Evaluation of the cognitive, psychomotor and phamracokinetic profiles of rupatadine,hydroxyzine and eetirizine, in combination with alcohol in healthy volunteers [J]. Hum Psychopharmacol, 2006, 21(1) :13-26.
  • 9IZQUIERDO I, MERLOS M,GARCIA-RAFANELL J. Rupatadine a new selective histamine H1 reeptor and platelet--activating factor (PAF) antagonist. A review of phamaeological profile and clinical management of allelgic rhinitis[J]. Drugs Today(Barn) , 2003, 39(6) : 451-468.
  • 10State Food and Drug Administration. Drug clinical trials quality management standard(药物临床实验质量管理规范)[S].2003:8.

共引文献16

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部